An expanded range of hard to find analytical standards of API impurities are now immediately available in gram quantities including those for phenylephrine

Being at the forefront when phenylephrine (PE) was introduced, Epichem is now the premier  supplier of analytical standards of PE impurities and degradants.

Moreover, Epichem has a wide range of impurities, degradants and metabolites for many other APIs, especially OTC products. Managing Director Dr Wayne Best commented: “In response to the many requests from our customers, we have developed this range of high purity analytical standards that are readily available to ship, importantly in multigram quantities if required. 

Epichem’s laboratory and quality systems have passed audits by four of the world’s largest pharmaceutical companies and our standards come with full supporting data and documentation. We understand that there is an unmet demand for these products and wanted to alert the industry to their availability.  Additionally, we have assisted a number of companies to identify trace impurities in new formulations and then synthesize standards for quantification, enabling them to register new products with the regulatory authorities.”

Range of Pharmaceutical standards

Epichem’s range of analytical standards are essential tools to meet regulatory requirements and determine better and more stable formulations for product development for the following APIs:

About Epichem

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited.  Located in Australia, Epichem has been delivering synthetic and medicinal chemistry services to the drug discovery and pharmaceutical industries for more than 7 years.  An array of multinational pharmaceutical clients and others in 18 countries from around the world use the services on a regular basis.  Epichem uses the most sophisticated laboratory instrumentation and world class expertise in synthetic and medicinal chemistry for the cost effective custom synthesis of drug analogue libraries and intermediates.  Epichem has considerable expertise and experience in drug discovery and is actively working with many clients and collaborators including the not-for-profit Drugs for Neglected Disease initiative (DNDi) as part of a consortium to find a cure for Chagas Disease.

For more information

Barry Epstein

BA (BioSci)

VP Marketing

Telephone +61 8 9360 7696

Mobile/Cell + 61 8 412 788 665

Facsimile +61 8 9360 7699

Email barry.epstein@epichem.com.au

Website  www.epichem.com.au

Source: web of pharmceutical outsourcing